Park occupiers have a ‘spring in their step’
Published on 28 March 2024
Recent updates showcase lots of potential within the scientific community at Milton Park. From groundbreaking therapies to financial growth, occupiers have a spring in their step at the Park.
Immunocore expands reach of key product
Immunocore, a leading biotech company headquartered at Milton Park, has announced the expansion of the world’s first approved TCR therapy, KIMMTRAK, with additional approvals, launches, and sales growth across all territories. The company reports robust financial results, with revenues from KIMMTRAK reaching $67.6 million in Q4 and $238.7 million in 2023.
CEO Bahija Jallal commented, “In the last five years, Immunocore has transformed from a research organisation to a revenue-generating, sustainable company. We look forward to the next five years, when we maximize the potential of KIMMTRAK, expect to launch our PRAME ImmTAC therapy, and advance our clinical candidates across oncology, infectious diseases and autoimmune diseases.”
Immunocore has also entered into a clinical trial collaboration with Bristol Myers Squibb for IMC-F106C, a promising therapy for advanced cutaneous melanoma, aiming to enhance treatment outcomes through innovative approaches. The company’s strategic expansion is supported by strong cash reserves of $442.6 million as of December 31, 2023, further bolstered by a recent Convertible Senior Notes offering.
Summit Therapeutics’ operational progress continues
Milton Park-based Summit Therapeutics shares updates on its fourth quarter and year-end financial results for 2023. This comes alongside significant operational progress, particularly with ivonescimab, a potential breakthrough in cancer treatment.
The company is proactively engaged in ivonescimab’s development, with multiple discussions with the US FDA over the past year regarding the planned Phase III clinical program. These efforts underscore Summit’s commitment to advancing innovative therapies, with ivonescimab poised to address critical unmet needs in cancer care, particularly in non-small cell lung cancer.
Financially, Summit has extended its cash reserves, ensuring operational funding through Q1 2025 and further bolstering its commitment to advancing ivonescimab.
Adaptimmune Therapeutics predicts $400m US peak year sales
Milton Park based Adaptimmune foresees significant success with pioneering cell therapy, set to transform solid tumour cancer treatment. CEO Adrian Rawcliffe predicts potential US peak year sales of up to $400 million for afami-cel, marking a pivotal milestone in the company’s commercial ambitions.
CEO Adrian Rawcliffe commented: “Afami-cel is the first product in our sarcoma franchise, which, if approved, along with lete-cel, has the potential to redefine the landscape for the treatment of advanced synovial sarcoma and MRCLS.
“This franchise, which is only the beginning of our commercial ambitions, is projected to deliver up to $400m in US peak year sales.”
In its latest financial results and operational updates, Adaptimmune emphasised its strategic momentum in establishing a sarcoma franchise. The company’s robust cash position and ongoing partnerships will ensure sustained operations into early 2026, reflecting its commitment to advancing innovative solutions in oncology.
